Download - Outreach Oct 2010
-
7/31/2019 Outreach Oct 2010
1/16
October 2010OUTREACH
1
OUTREACHVOl X issUE iii OCTObER 2010
Record numer of advocate
ray on Capto H forPancreatc CancerAdvocacy Day 2010
-
7/31/2019 Outreach Oct 2010
2/16
Dear Pancreatic Cancer Action Network Friends:
Thanks to the inspiring generosity of our stellar donors
and support of volunteers nationwide, our 2009-10 scal
year, that ended on June 30, was another successful one
for the organization. I want to personally acknowledge
everyone who contributed for their benevolence in helping
to further the organizations mission.
These donations helped to fund one of the important aims of the Pancreatic Cancer
Action Network: our research grants program. In 2010, approximately $2.3 million
was incurred to fund research grants awarded to outstanding investigators. To
learn more about our 2011 research grants program, please see page 1.
In other news, the endorsement of a respected celebrity is helping to further
raise the organizations prole. Writer, director and best-selling author Lisa Niemi
Swayze, who lost her husband, Patrick Swayze, to pancreatic cancer in 2009, has
agreed to serve as our spokesperson. We are extremely grateful for her support
and dedication.
You may have received a heartfelt e-mail from Lisa on September 14, the
rst anniversary of Patricks death, urging you to be a hero in the ght against
pancreatic cancer. Lisa kicked off our November awareness campaign with a
special message about the urgent need to ght the disease and with a touching
video promoting our theme: Be a Hero in the Fight Against Pancreatic Cancer.
Know It. Fight It. End It. (Watch Lisa's video at www.knowitnditendit.org.) We are
excited that Lisa is lending her voice to our cause and this campaign. To nd out
how you can take action this November as part of the campaign, turn to page 6.
As always, your ongoing support and generosity, enabling us to continue providing
much-needed, high-quality services and programs for the pancreatic cancer
community, is deeply appreciated.
Sincerely,
Jason Kuhn
Board Chair
P.S. Congratulations to David Tuveson, MD, PhD, who began serving a two-year
term as the chair of the organization's Scientic Advisory Board in July. Look for
more information about Dr. Tuveson's appointment in the February 2011 issue of
Outreach.
BOARD OF DIRECTORSJason Kuhn, Chair, Tampa, Fla.
Stephanie R. Davis, JD, MA, Secretary,
Sherman Oaks, Calif.
Tim Ennis, Boca Raton, Fla.
Julie Fleshman, JD, MBA, President & CEO
Los Angeles
Stevan Holmberg, MBA, DBA, Potomac, M
Peter Kovler, Washington, D.C.
Laurie MacCaskill, Los Angeles
Jai Pausch, Hampton Roads, Va.
Stuart Rickerson, Rancho Santa Fe, Calif.
Cynthia Stroum, Founding Chair Emeritus,
Seattle
SCIENTIFIC ADVISORY BOARDDavid Tuveson, MD, PhD, Chair,
Cambridge Research Institute/CRUK
Dafna Bar-Sagi, PhD, New York University
Teri Brentnall, MD, University of WashingtoMichael Hollingsworth, PhD,
University of Nebraska Medical Center
Ralph Hruban, MD, Johns Hopkins Univers
Elizabeth Jaffee, MD, Johns Hopkins Unive
Craig Logsdon, PhD,
MD Anderson Cancer Center
Margaret Mandelson, PhD,
Fred Hutchinson Cancer Research Cent
Gloria Petersen, PhD, Mayo Clinic
Margaret Tempero, MD,
University of California, San Francisco
Selwyn Vickers, MD, University of Minneso
Geoffrey Wahl, PhD, Salk Institute
MEDICAL ADVISORY COUNCILMark Talamonti, MD, Chair,
NorthShore University HealthSystem
Jordan Berlin, MD,
Vanderbilt-Ingram Cancer Center
Marcia Canto, MD, Johns Hopkins Univers
Christopher Crane, MD,
MD Anderson Cancer Center
Jason Fleming, MD,
MD Anderson Cancer Center
Julie Meddles, RD, LD,
Ohio State University Medical Center
Mary Mulcahy, MD,
Northwestern University
Maria Petzel, RD, CSO, LD, CNSD,
MD Anderson Cancer Center
Vincent Picozzi, MD,
Virginia Mason Medical Center
Mark Pochapin, MD, Jay Monahan Center
Gastrointestinal Health
CHAIRS MESSAGECELEBRATING ANOTHER SUCCESSFUL YEAR
OUR MISSIONThe Pancreatic Cancer Action Network is a nationwide network of people dedicated to working together
to advance research, support patients and create hope for those affected by pancreatic cancer.Cover image: Angela Johnson
www.redboatimages.com
-
7/31/2019 Outreach Oct 2010
3/16
October 2010 OUTREACH 1
The Pancreatic Cancer Action Network has committed al-
most $3 million to research through its 2011 grants program,representing a 30 percent increase compared to 2010 funding.
Since the inception of its grants program in 2003, the
organization has awarded 56 grants totaling more than
$7.2 million to scientists across the country.
As the 2010 grant recipients embark on their proposed
research projects, another group of highly talented scientists
and clinicians will soon be welcomed into the organizations
research family. The grants program addresses two major
barriers to research progress in pancreatic cancer a sparse
research community and limited funding by attracting and
retaining bright investigators to study pancreatic cancer, and
supporting their research endeavors to accelerate scienticbreakthroughs.
In addition to providing funding for research projects, the
Pancreatic Cancer Action Network also strives to mold future
leaders in the eld. Three of the research grant mechanisms
are specically designed to support promising scientists
early in their careers: Fellowship, Career Development, and
Pathway to Leadership awards. Attracting young research-
ers to pursue careers focused on pancreatic cancer is an
ongoing goal of the organization. To accomplish this, mentor
relationships are fostered between young researchers and
more senior scientists, based on common research interests.
Further, grant recipients are given multiple opportunities
to interact and present their work to members of the
organizations Scientic Advisory Board and Medical
Advisory Council, gaining invaluable insights, advice and the
potential for future collaborations.
The nal grant mechanism is the Innovative Grant, for-
merly known as the Pilot Grant. Innovative Grants support
projects that are novel, pose questions that have not yet
been addressed, or utilize unconventional experimental ap-
proaches. Independent investigators at any stage of their
careers are eligible for Innovative Grants. This mechanism
also invites cancer researchers focused on other tumor typesto apply their knowledge and expertise to pancreatic cancer,
further strengthening and expanding the pancreatic cancer
research community. (Note: By press time, the deadline for
Letters of Intent for the Innovative Grant had passed.)
The 2011 Pancreatic Cancer Action Network grants will
once again be administered in partnership with the American
Association for Cancer Research (AACR). AACRs involve-
ment ensures unbiased funding of the most meritorious
research projects, via a rigorous peer-review system, empha-
sizing originality and scientic credibility.
Grant applications must be submitted online through
proposalCENTRAL (https://proposalcentral.altum.com). Thegrant terms start July 1, 2011.
For additional information, visit http://www.pancan.org/grants
or contact Rhonda Aizenberg, PhD, at [email protected].
To learn more about opportunities to provide nancial support
for our research program, contact Pamela Acosta Marquardt at
NEARLY $3 MILLION COMMITTED TO RESEARCH FOR 2011APPLICATION DEADLINE IS OCTOBER 27 FOR MOST GRANTS
2011 GRANTS PROGRAM FUNDING OPPORTUNITIES
Pathway to Leadership Grant
Up to ve years of support totaling $600,000 for a
highly promising early career scientist beginning in a
postdoctoral position and continuing through transition
to independence.
Eligibility: Applicant must be in the rst ve years of a
postdoctoral or clinical research fellowship (i.e., started
a fellowship on or after July 2, 2006) at the beginning of
the grant term.
Application Deadline: October 27, 2010, Noon ET
Fellowship Award
One-year grant totaling $45,000 for an early career
scientist to support his/her mentored research.
Eligibility: Applicant must be in the rst three years of a
postdoctoral or clinical research fellowship (i.e., started
fellowship on or after July 2, 2008) at the beginning of
the grant term.
Application Deadline: October 27, 2010, Noon ET
Career Development Award
Two-year grant totaling $200,000 for a newly indepen-
dent investigator to develop or strengthen a research
program in pancreatic cancer.
Eligibility:Applicant must be in the rst four years of a
faculty appointment (i.e., completed postdoctoral/clini-
cal fellowship on or after July 2, 2007) at the beginning
of the grant term.
Application Deadline: October 27, 2010, Noon ET
Innovative Grant
Two-year grant totaling $200,000 intended to further
the development of new and innovative ideas and
approaches, including those successful in other areas of
cancer that show promise for pancreatic cancer.
Eligibility: Applicant must be an independent junior or
senior investigator (not including postdoctoral/clinical
fellows).
Letter of Intent Deadline: Closed
-
7/31/2019 Outreach Oct 2010
4/16
2 October 2010 OUTREACH
Dr. McCormick received the2010 Fredman Family Founda-
tion Pancreatic Cancer Action
Network AACR Innovative
Grant. The author of several of
the most widely cited papers in
cancer biology, Dr. McCormick
has revolutionized understand-
ing of cancer-causing viruses
and identied important regu-
lators of a signaling pathway
altered in many cancer types,
including pancreatic cancer. He founded Onyx Pharmaceu-ticals in 1992, where he developed a drug commonly used to
treat certain kidney and liver cancers. When the University
of California, San Francisco Helen Diller Family Comprehen-
sive Cancer Center was founded in 1998, Dr. McCormick was
recruited to serve as its director, a position he still holds.
While several of the Pancreatic Cancer Action Network
grant mechanisms cater to young scientists early in their
careers, the Innovative Grant is open to independent inves-
tigators at any career level. The purpose of this award is
to support creative ideas and unconventional experimental
approaches. This funding opportunity welcomes projects
proposed by more senior investigators for whom pancreatic
cancer has not previously been a primary research focus.
The knowledge and experience provided by these scientists
can greatly enhance progress in pancreatic cancer research.
The Innovative Grant is a perfect t for Dr. McCormick.
A great deal of his work has focused on a cell signaling
pathway involving a protein called Ras. This protein plays
a critical role in signaling that ultimately results in growth,
survival, movement, and other cellular properties that, whenaltered, are traits of cancer cells. Dr. McCormick con-
tributed greatly to the understanding of this pathway by
discovering and characterizing additional proteins that are
involved in positively and negatively regulating the activated
state of Ras. Mutations of Ras and alterations of Ras path-
way members are extremely common in cancer, especially
pancreatic.
In fact, the specic Ras family protein called K-Ras has
been shown to be mutated in up to 90 percent of pancre-
atic tumors. It is well established that K-Ras plays a crucial
role in the initiation and maintenance of pancreatic cancer.
Because of cancer cells dependence on K-Ras signaling,the protein makes an attractive candidate as a therapeutic
target. However, previous attempts at targeting K-Ras in
pancreatic and other cancers have been unsuccessful.
For his funded project, Dr. McCormick proposes devel-
oping a drug to block K-Ras in an unconventional manner.
Investigators know that the K-Ras protein must be embedded
in the cell membrane in order to become active. Rather than
attempt to block the protein activity directly, McCormick aims
to create a drug that will bind to K-Ras and physically impede
its attachment to the cell membrane. McCormick calls his
strategy a new attack on an old target.
When asked what advice he would give to early-career
scientists focused on pancreatic cancer, McCormick shared
a simple message: Now is the time. We have the best knowl-
edge, best tools at our disposal to try to make an impact.
K-Ras has proven to be an elusive target to other cancer
researchers. Previously, Dr. McCormick focused his atten-
tion on observing and understanding Ras and its signaling
partners. He is now motivated to nd a novel way to block
K-Ras activity as a means to treat pancreatic cancer.
MEET A GRANTEEFRANK MCCORMICK, PHD, FRS: LAUNCHING A NEW ATTACK ON K-RAS
Frank McCormick, PhD, FRS
Fredman family
Last year, our family funded our rst research grant through thePancreatic Cancer Action Network after losing our beautiful mother topancreatic cancer. We found comfort in supporting the work of thismost worthy organization while at the same time paying tribute to herThis year, we are thrilled to be able to fund an even larger grant tosupport the innovative thinking that we feel is necessary to one daynd a cure. Our family is honored to play a role in helping to shapewhat is needed to stop this insidious disease.
Fredman Family Foundation (in honor of Ruth Fredman Cernea)
-
7/31/2019 Outreach Oct 2010
5/16
October 2010 OUTREACH 3
As one of the countrys leading cancer killers, pancreatic
cancer presents a signicant challenge for scientists andclinicians to understand, diagnose, and treat. While great
strides have been made in ghting other forms of cancer in
recent years, breakthroughs in pancreatic cancer have elud-
ed investigators.
Pancreatic cancer research has lagged behind that of
other cancer types for multiple reasons. First, people do not
generally pay much attention to the pancreas. The same
goes for doctors, who do not have the means to routinely
check their patients pancreatic health. If present, symptoms
of pancreatic cancer are often quite nonspecic, leading to
tragic delays in diagnosis.
Because of the location and diverse functions of the
organ, and a lack of obvious symptoms, the majority of pan-
creatic tumors are diagnosed late, when surgery is no longer
a feasible option. Surgery is the most effective way to treat
pancreatic cancer, but the majority of patients are not viable
candidates. Although numerous combinations of chemo-
therapeutics, targeted drugs, and radiation have been tested
to treat pancreatic cancer, few benecial treatment options
currently exist.
Improved diagnostic tools and therapies have revolu-
tionized the management of other cancer types. Bright and
hard-working doctors and scientists worldwide tirelessly
strive to bring the same successes to pancreatic cancer.
However, none of these advances will be possible without
adequate funding and other needed resources.
The vast majority of biomedical research conducted in the
United States is funded by the government, via the NationalInstitutes of Health (NIH). Within the NIH, the National Cancer
Institute (NCI) supports research on cancer.
In 2009, the NCI dedicated a mere two percent of its total
budget to research grants focused on pancreatic cancer. For
decades, pancreatic cancer has received a similar fraction
of NCI dollars, representing dramatically less funding than its
societal health toll demands. The funding awarded to other
cancer types, such as breast and prostate, eclipses that allot-
ted to pancreatic cancer. Consequently, the diseases which
receive the larger amounts of funding generally see greater re-
search advancements and subsequent clinical improvements.
The successes seen in breast, prostate, and other cancer
types serve as evidence that the appropriate combination of
bright minds, hard work, and ample research funds can and
will lead to similar advances in pancreatic cancer diagnosis
and treatment.
Through its grants program, the Pancreatic Cancer Action
Network is dedicated to attracting and retaining bright scien-
tists to study pancreatic cancer. (See page 1.) Additionally,
the organization encourages increased federal research fund-
ing by meeting directly with the NCI staff, educating Members
of Congress and promoting legislation urging the NCI to create
a strategic plan and targeted research program to address
pancreatic cancer. The combination of these efforts with en-
hanced cooperation from the NCI will be necessary to make
pancreatic cancer progress a reality.
INCREASED FEDERAL FUNDING URGENTLYNEEDED FOR PANCREATIC CANCER RESEARCH
Stand Up To Cancer (SU2C), a charitable
initiative of the Entertainment Industry
Foundation, was formed in 2008 to support
groundbreaking research aimed at delivering new cancer
treatments to patients in an accelerated timeframe.
In 2009, SU2C awarded an unprecedented $18 million
grant to fund a scientic dream team focused on studying pan-
creatic cancer. The pancreatic cancer dream team comprises
scientists from notable institutions across the U.S. and is led
by Daniel Von Hoff, MD, Director of the Clinical Translational
Research Division at the Translational Genomics Research
Institute (TGen), and Craig Thompson, MD, Director of the
Abramson Cancer Center at the University of Pennsylvania.
The researchers on this team are working to better
understand how pancreatic tumors utilize glucose and/
or glutamine as fuel. Meanwhile, members of the team
at Johns Hopkins University (Drs. Dan Laheru and Ana
De Jesus) recently opened a Phase II clinical trial to test
the effectiveness of a new targeted agent in patients with
metastatic pancreatic cancer.
The Phase II trial involves a new drug targeting the
hedgehog pathway, called GDC-0449, used in combination
with gemcitabine (Gemzar) and nab-paclitaxel (Abraxane).
Scientists have demonstrated that the hedgehog pathway
plays a role in maintaining a dense layer around the tumor,
which is thought to prevent drug delivery to it.
To learn more about this clinical trial or other pancreatic
cancer treatment options, contact the Pancreatic Cancer
Action Network's PALS program toll-free at 877-272-6226, M-F
7am-5pm Pacic Time or e-mail [email protected].
SU2C DREAM TEAM OPENS CLINICAL TRIAL
-
7/31/2019 Outreach Oct 2010
6/16
4 October 2010 OUTREACH
Nearly 1,000 Pancreatic Cancer Action Network supporters
from across the nation joined forces to support the fourth
annual Pancreatic Cancer Advocacy Day and the National
Call-In in June.
On June 21, more than 400 advocates gathered in
Washington, D.C. and were trained on up-to-the-minute
advocacy messaging,
C o n g r e s s i o n a l
s t r a t e g y , a n d
powerful ways of
strengthening the
impact of advocacy
efforts in their owncommunit ies. The
fol lowing day, the
supporters traveled
to Capitol Hill to share
t h e i r s t o r i e s a n d
ask their Senators
and Representatives
to co-sponsor the
Pancreatic Cancer
Research & Education
Ac t (S . 3220 /H .R .
745), a bill thatwill ensure that the
National Cancer
Institute (NCI) creates a strategic plan to make progress in
pancreatic cancer research.
During the National Call-In on June 22,
more than 2,000 calls were placed to
more than 340 Congressional ofces,
echoing similar requests that were put
forth during the in-person meetings with
legislators in Washington, D.C. The
combined efforts resulted in securing
the support of more than half of the U.S.
House of Representatives and one-fth of
the U.S. Senate for the bill. The efforts
also enabled us to begin an impressive
push forward to call for Congress to bring
the bill to a vote.
Now that we have secured signicant
bi-partisan support for the Pancreatic
Cancer Research & Education Act, it is even more important
that we continue our efforts, said Megan Gordon Don,
Director of Government Affairs & Advocacy. First, we need
you to ask your U.S. Representative to do everything that they
can to bring H.R. 745 to a vote and to get it passed before
they return home this year. If the bill doesnt pass before the
House adjourns, though, well need to work together to get
all of our co-sponsors back on board, as well as many new
ones when they return in January 2011.
Well keep you posted on the latest developments at
www.pancan.org/TakeAction, she added. Well need your
help either way. This is truly an exciting time to be involvedin advocacy. When the bill passes, not only will it mean
critical pancreatic cancer research funding and essential
accountability at the NCI, but we will be able to celebrate
having made history together.
FOURTH ANNUAL PANCREATIC CANCER ADVOCACY DAY ANDNATIONAL CALL-IN HAILED AS NOTABLE SUCCESS
Pancreatic Cancer Advocacy Day participants who met with Rep. Bill Foster (D-IL), third from left,
included, from left, Medical Advisory Council Chair Mark Talamonti, MD, survivor Judy Sarvas, Claudia
Trapp, Brittney Talamonti, Jason Talamonti and Anne Talamonti.
Capitol Hill was awash in purple on June22, when more than 400 advocates carried
bags with advocacy messaging.
The Pancreatic Cancer Research & Education Act
(S. 3320/H.R.745)
U.S. Senators co-sponsoring*:
26%(26/100 Senators)U.S. Representatives co-sponsoring*:
56.3%(245/435 Reps.)*As of Sept. 30, 2010
-
7/31/2019 Outreach Oct 2010
7/16
October 2010 OUTREACH 5
SAVE THE DATEPancreatic Cancer Advocacy Day 2011June 13 and 14 Washington, D.C.Registration opens during Winter 2011.
To learn more, visit www.pancan.org/AdvocacyDay
Twin Cities Afliate advocate and PurpleRide Minneapolis Co-founder Renita
Van Dusen gestures as she boards a bus bound for Capitol Hill.
Pancreatic Cancer Action Network Board Member Jai Pausch prepares her
son, Dylan, before he speaks as his brother, Logan, looks on at Advocacy
Day training.
Boston Advocacy Coordinator Yadhav Jayaraman and his family appeared
at several Congressional meetings during Advocacy Day.
From left, advocate Fred Brindisi, Pancreatic Cancer Action Network Board
Member and survivor Stuart Rickerson, and advocate Silvana Brindisi strat-
egize for their meetings with their Members of Congress.
Boise Afliate Coordinator and survivor John Bradley advocated with his
sons Ian and Rae at the event.
Senate Majority Leader Senator Harry Reid (D-NV), second from left, met
with advocates, from left, Lisa Hamburg, survivor Stuart Jed, Shannon
Wood, Pancreatic Cancer Action Network President and CEO Julie Flesh-
man and Ginnie Jed.
-
7/31/2019 Outreach Oct 2010
8/16
6 October 2010 OUTREACH
BE A HERO THIS FALLOn September 14, the Pancreatic Cancer Action Network
launched its annual fall campaign designed to raise
awareness, increase advocacy and grow the community of
supporters committed to nding a cure for pancreatic cancer.
As with the 2009 campaign, an interactive, user-friendly site
was created that not only engages visitors, but gives them the
tools they need to become effective advocates for the cause.
The campaign precedes Pancreatic Cancer Awareness
Month in November.
This years theme is Be a Hero in the Fight Against
Pancreatic Cancer: Know It. Fight It. End It. The campaign
will focus on two areas: 1.) engaging supporters to explain
why they or their loved ones
are heroes in the ght and 2.)
activating the organizations
base of supporters to take one
simple action every day be-tween the launch of the Hero
campaign on September 14
and November 30 to heighten
awareness of the disease.
We want to show peo-
ple that not only can anyone
be a hero in the ght against
pancreatic cancer, but that to-
gether we are an even stronger
force that can make a real dif-
ference, said Lisa Gilmour,
Director of Marketing and Com-munications. On the homepage of our Hero website, well
feature ve personal videos, which started with the launch
of a touching message from Lisa Niemi Swayze on Septem-
ber 14, the rst anniversary of the passing of her husband,
Patrick Swayze. We are thrilled that Lisa has agreed to sup-
port the Pancreatic Cancer Action Network to honor Patricks
memory and to help further our mission by bringing more at-
tention to the disease.
Other supporters can also help spread the word by visiting
the organizations new Hero website at
www.knowitghtitendit.org to nd simple yet highly impact-
ful actions anyone can take to help make a difference. These
include sending a letter to your elected ofcials, wearing pur-
ple to work, mailing a letter to the editor of your local paper,
or forwarding the many compelling and personal hero stories
on our website to friends and family to help spread the word
about the need for more aware-
ness, Lisa Gilmour added.
An interactive, download-
able action calendar featuring
suggestions for daily activitiesis also available on the site. The
calendar offers advocates, vol-
unteers and supporters a wide
variety of ways to take action,
with a strong focus on advocacy
actions to reach out to elected
ofcials about the need to co-
sponsor the Pancreatic Cancer
Research & Education Act.
In addition to the calendar,
patient and supporter stories
will be featured throughout thesite, along with additional information and resources about
other ways to become an advocate for the cure.
Do your part today and encourage everyone you know to
visit www.knowitghtitendit.org .
LISA NIEMI SWAYZE TO SERVE AS ORGANIZATION SPOKESPERSO
Writer, director and best-selling author Lisa Niemi Swayze will serve as a spokesperson for the Pancreatic CanAction Network to build awareness of the disease that took the life of her husband, Patrick Swayze, in 2009.
In addition to helping launch the organizations annual fall campaign that precedes Pancreatic Cancer AwarenMonth in November, Lisa will be presented with the Pancreatic Cancer Action Network's Spirit of Hope Award at 13th annual An Evening with the Stars gala on October 30. She will also appear in public service announcemeand serve as a guest speaker at various events for the organization.
I joined forces with the Pancreatic Cancer Action Network in honor of Patrick, because I know it would meanlot to him if his illness made a difference in the lives of others, Lisa said. My involvement is the best way I knof to make progress in ghting this terrible disease.
Along with Patrick, Lisa co-wrote his memoir entitled "The Time of My Life," which provides a behind-the-scenes look at their successHollywood and their remarkable love story. The book was a New York Times" Best Seller, debuting at number four on the newspaper's las well as an international best seller.
Lisa currently divides her time between Los Angeles and her ranch in New Mexico.
-
7/31/2019 Outreach Oct 2010
9/16
October 2010 OUTREACH 7
The Patient and Liaison Services (PALS) program of the
Pancreatic Cancer Action Network is pleased to announce
the launch of an innovative outreach effort called the Patient
Navigation Outreach Program. The endeavor is intended
to improve certain patterns of pancreatic cancer diagnosis
and treatment and ensure that pancreatic cancer patients
and their caregivers are made aware of the resources and
information available through the PALS program.
Healthcare professionals not only play a critical role in
the diagnosis and care of pancreatic cancer patients but are
also uniquely positioned to refer them and their caregivers
to useful resources and support services. Therefore, the
program will focus on equipping the healthcare community
with the information, tools and resources they can use to
effectively meet the needs of pancreatic cancer patients and
their caregivers.Pancreatic cancer is very difcult to diagnose, with no
established screening or early detection tools. Diagnosis is
often made in the late stages of the disease. The rst goal
of the program is to encourage healthcare professionals to
appropriately consider pancreatic cancer when diagnosing a
patient with specic symptoms. By encouraging physicians
to keep pancreatic cancer in mind and to consider the disease
as a possible diagnosis when examining their patients, we
hope to shorten the length of time between an initial doctors
visit and an eventual diagnosis of pancreatic cancer, said
Anitra Talley, Director of the PALS program.
The second goal of the program is to encouragephysicians who are diagnosing pancreatic cancer patients
to refer them to a surgeon who treats a high volume of
pancreatic cancer patients, to an oncologist who focuses
on gastrointestinal or pancreatic cancer, or to an institution
conducting clinical trials for pancreatic cancer. This approach
will ensure that such patients are made aware of treatment
options available to them and are able to make informed
decisions about their care.
Lastly, the third goal of the Patient Navigation Outreach
Program is to continue to raise awareness about the PALS
program among healthcare professionals so more patients
facing the disease have access to its services.
Through a cost-free information line, the PALS
program provides personalized, up-to-date information
about the disease, clinical trials, treatment options, diet
and nutrition, side
effect and symptom
management and
support resources.
The PALS program
educates pancreatic
cancer patients andtheir caregivers about
many aspects of the
disease and connects them with needed resources so that
they are well-equipped and empowered to make informed
decisions about care and treatment.
To deliver the messages aligned with the program
to a broad audience of healthcare professionals, PALS will
use a variety of tactics to heighten awareness, Tally added.
These outreach methods will include a far-reaching media
campaign, new educational materials, in-person outreach
at medical meetings and conferences, targeted mailings
and community-level outreach performed by volunteers incommunities nationwide.
For more information about the Patient Navigation
Outreach Program or to contact a PALS Associate for
information about pancreatic cancer, call PALS toll-free
at 877-272-6226, Monday-Friday from 7am-5pm Pacic
Time or e-mail [email protected].
PATIENT NAVIGATION OUTREACH PROGRAM LAUNCHED
The Palette Fund, a foundation that honors the legacy of
Rand Skolnick, who died from pancreatic cancer in 2008,
has graciously partnered with the Pancreatic Cancer Action
Network to fund the Patient Navigation Outreach Program.
We are deeply grateful to The Palette Fund for funding this
important program, said Anitra Talley, Director of the Patient
and Liaison Services (PALS) program. Through their generos-
ity, Rands vision is being realized, and his philanthropic legacy
is honored through collaborative grant-making and programs
that value human rights and education. This program denitely
furthers these goals, as it will positively impact the thousands
of people who must face this disease each year.
The Palette Fund hopes to create a groundswell of con-
sciousness and change to nd new ways to bring Rands
philanthropic legacy and aid to as many people and causes
as possible, as well as to inspire people to join a grassroots
movement to help others in need. In the end, they hope that
one mans death will better the lives of thousands of others.
The pancreatic cancer community will undoubtedly
benet in countless ways because of the generosity and
commitment of The Palette Fund and their vision to support
the Patient Navigation Outreach Program as a tribute to the
memory of Rand, she added.
To nd out more, visit www.thepalettefund.org.
THE PALETTE FUND SUPPORTS INNOVATIVE NEW PROGRAM
-
7/31/2019 Outreach Oct 2010
10/16
8 October 2010 OUTREACH
PANCREATIC CANCER STUDY RESULTS PRESENTED ATAMERICAN SOCIETY OF CLINICAL ONCOLOGY MEETINGAt the American Society of Clinical Oncology (ASCO) Annual
Meeting, held in Chicago from June 4 to 8, 2010, investigators
shared results of several clinical trials for the treatment ofpancreatic adenocarcinoma. Summaries of a selection of
these studies appear below.
PHASE III RESULTS
In a Phase III study conducted in France, metastatic
pancreatic cancer patients who were treated with a
chemotherapy regimen called FOLFIRINOX, consisting of
the drugs 5-FU, leucovorin, irinotecan and oxaliplatin, were
compared to patients treated with the current standard of
care, gemcitabine (Gemzar) alone. All 342 patients enrolled
in the study were otherwise healthy and had received no
previous treatment.
Encouragingly, patients treated with the FOLFIRINOX
regimen survived 11.1 months on average, compared to 6.8
months for those treated with gemcitabine. These results
suggest that FOLFIRINOX may be considered for those with
metastatic pancreatic cancer who are healthy enough to
withstand potential side effects. This study reected the rst
positive Phase III clinical trial for such patients since 2005.
Patients treated with FOLFIRINOX experienced worse,
yet manageable, side effects. These side effects included
low white-blood cell and platelet count, vomiting, fatigue,
diarrhea and numbness or pain in the hands and feet.
Another Phase III trial, conducted in Germany, enrolled 281
patients with locally advanced or metastatic pancreatic
cancer. The rst group was treated with gemcitabine plus
erlotinib (Tarceva) followed by capecitabine (Xeloda), a
common treatment regimen. The second, and experimental,
group was treated with capecitabine plus erlotinib, followed
by gemcitabine. In both groups, the patients were initially
treated with the combination therapies and then received the
second-line drug if their cancer progressed.
Study investigators compared the length of time until the
second-line treatment was discontinued in each group.
They sought to determine if this length of time would be
non-inferior in the experimental group. The non-inferiority of
the experimental group was demonstrated and the patients
overall survival was comparable between the arms.
The study did not reveal a new treatment regimen but
showed that investigators may choose to consider building
on capecitabine when developing new rst-line regimens.
PHASE II RESULTS
A Phase II study presented at the meeting compared
gemcitabine alone to two other combinations: a targeted
therapy drug called conatumumab plus gemcitabine,
and another targeted therapy drug called AMG 479 plus
gemcitabine. This study evaluated 125 otherwise healthy
patients with metastatic pancreatic cancer who had not
received prior treatment.
Researchers wanted to learn if either of the new combinations
showed better overall survival than gemcitabine alone. No
signicant differences in overall survival were seen, but
investigators did see a trend towards longer length of time
before the disease began to progress in both combination
arms. While more information is needed to draw any
conclusions about these regimens, the combinations were
well tolerated and warrant further study.
Additionally, a Phase I/II study of Rexin-G, a targeted genetic
drug, was presented. This study looked at the safety and
efcacy of Rexin-G as a treatment for metastatic pancreatic
cancer that progressed after treatment with gemcitabine.
Fifteen patients were given one of three dose-levels of
Rexin-G for four weeks followed by additional treatment if
they did not experience signicant side effects.
Overall, no signicant toxicities were seen and there
appeared to be a correlation between overall survival and the
cumulative amount of Rexin-G administered. This evidence
suggests that Rexin-G may control tumor growth and prolong
survival, so further clinical studies are warranted.
For more information about these studies or treatment
options, or for a personalized clinical trial search, contact
Patient and Liaison Services (PALS) toll-free Monday-
Friday from 7am-5pm, Pacic Time, at 877-272-6226 or
e-mail [email protected].
UPCOMING 2011 PANCREATIC CANCER EDUCATIONAL EVENTS
Go to www.pancan.org for more information and to register.Information about fall educational lectures held nationwide is available as well.
ChicagoApril 15/ Hyatt Regency Chicago
Join us for information presented by leaders in the eld and networking opportunities with otherpatients, survivors, caregivers and family members.
Washington, D.C.March 19/ Renaissance Washington, D.C.
SeattleMay 20/ Sheraton Seattle Hotel
-
7/31/2019 Outreach Oct 2010
11/16
October 2010 OUTREACH 9
In April 2005, at the age of 65, I experienced the rst indica-
tion that something was wrong with my health. At that time,
several people approached me at a youth baseball game and
mentioned, You must be playing a lot of golf lately because
youve got a tan. My wife said it was actually yellow, not tan.
An internists exam conrmed I did not have a suntan but
jaundice, and I was referred to a gastroenterologist for tests to
determine the cause. This doctors opinion was that my prob-
lem was caused by one of three things: gallstones, cancer in
the bile duct or pancreatic cancer. Soon, I was sent to a local
hospital for surgery.
Despite the surgeons positive outlook, I had only been in
surgery for an hour when the doctors found that a st-sized
tumor on my pancreas was too large and too close to a major
blood vessel to be removed. So the surgeon inserted a tem-
porary bypass around the tumor, closed me up and said it was
incurable and I had six months to a year to live. They sug-
gested chemotherapy and radiation to extend my life.
During that period of both chemotherapy and radiation
treatments, friends and family convinced me to get a second
opinion from a doctor who specialized in pancreatic cancer.
So I made an appointment at a regional comprehensive cancercenter with a surgeon who specialized in pancreatic surgeries.
However, because of the location of the tumor and my age,
the prospect of surgery remained daunting. I remember the
second surgeon asking me how badly I wanted to live, since
the surgery is difcult and so is the recovery.
During this stressful time, my wife was my biggest sup-
porter. She said we were going to ght this disease to the
last day. When one has that kind of emotional support, that is
half the battle. In January 2006, the tumor had shrunk to one
centimeter and I underwent a successful Whipple procedure.
The doctors said that I was cancer-free.
About six months later, in July of 2006, I was shocked to
learn that the cancer had returned to my liver. Under the care
of a new oncologist, I was prescribed a more aggressive regi-
men of chemotherapy and a targeted drug in pill form called
Tarceva. By January 2007, a CT scan determined the spots
on my liver had disappeared, so I stopped chemotherapy but
stayed on the daily Tarceva pill.
My cancer was no longer visible and my life pretty much
returned to normal. A few months later, however, I experi-
enced yet another reoccurrence of cancer in the bile duct and
I went through another six months of chemotherapy, which I
successfully completed in September 2007.
My experience with pancreatic cancer is a continual jour-
ney. When one goes through something like this, it changes
ones whole perspective on life. I knew the statistics, but Im
proud to be a ve-year survivor. I also credit my faith and my
familys support for helping me to beat those statistics. This
year I will be celebrating my 71st birthday and my wife and
I will celebrate our 48th wedding anniversary. I want to tell
other pancreatic cancer patients never to give up and to live
life to the fullest every day.
A STORY OF HOPE AND INSPIRATIONBy Denny LaVercombe, Helena, Ala.
PATIENT AND LIAISON SERVICES (PALS)Looking for information about pancreatic cancer? PALS offers comprehensive, high-quality information
resources for patients and caregivers facing pancreatic cancer, including information about the dise
treatment options, clinical trials, side effect and symptom management, diet and nutrition, and sup
resources. To learn more or to order a complimentary education packet, contact a PALS Associate.
El programa de PALS esta disponible en espaol.
Patient and Liaison Services (PALS)
Monday - Friday, 7am - 5pm Pacic Time
Toll-free: 877-272-6226 | E-mail: [email protected]
Denny and Jan LaVercombe with their grandchildren, from left,
Chris, Amber, Kailey, Trent and Grant
-
7/31/2019 Outreach Oct 2010
12/16
10 October 2010 OUTREACH
CONGRATULATIONS TO OUR VOLUNTEER LEADERSThanks are due to the following volunteers who began new leadership roles from June 1 to August 31, 2010.Betsy Anteau, Event Coordinator, Indianapolis
Terri Bertoli, Community Representative, TucsonKatie Boucher, Education/Outreach Coordinator,
Providence
Elisa Bowling, Education/Outreach Coordinator, AtlantaJohn Bradley, Afliate Coordinator, Boise
Kathryn Brekle, Event Coordinator, Birmingham
Brenda Coleman, Afliate Coordinator, Twin Cities (MN)Heather Costello, Education/Outreach Coordinator,
Columbus
Lisa Carranza-Habib, Community Representative, Jackson
(WY)Erin Corwin, Afliate Coordinator, Cleveland
Amy Cunningham, Education/Outreach Coordinator,
PhiladelphiaWhitney Davidson, Media Representative, Birmingham
Danielle Dietz, Event Coordinator, Los Angeles
Emily Hanson, Media Representative, ColumbusPaige Hawkins, Education and Outreach Coordinator,
Richmond (VA)
Ginnie Jed, Community Representative, Reno-Tahoe
Kira Johns, Education/Outreach Coordinator, ColumbusTeri Larson, Education/Outreach Coordinator, Twin Cities (MN)
Dennis LaVercombe, Advocacy Coordinator, Birmingham
Feme Liaz, Event Coordinator, PhiladelphiaMichelle Lozano, Event Coordinator, Houston
Tara Maloney Wheeler, Afliate Coordinator, Wilmingon (DE)
Suzy Marshall, Community Representative, HonoluluKimberly McFadden, Community Representative,
Anchorage
Justen Meyer, Event Coordinator, St. LouisDaniel Morris, Media Representative, Boise
Diane Pursel, Event Coordinator, Omaha
Kara Rocha, Event Coordinator, Providence
Diane Schooley-Pettis, Education and OutreachCoordinator, Boise
Eric Stark, Event Coordinator, Boise
Wendy Stoneberg, Advocacy Coordinator, BoiseMichael Timmermann, Media Representative, Los Angeles
Kim Trupiano, Media Representative, Providence
Lori Turner, Community Representative, CharlotteMargot Vela, Event Coordinator, Houston
Elaine Wencil, Education and Outreach Coordinator,
Philadelphia
Gibbie Whelehan, Community Representative, Salt Lake CityTeresa Young, Event Coordinator, Cleveland
VOLUNTEERING FOR LEADERSHIPThe Pancreatic Cancer Action Network is grateful for the
support of thousands of volunteers actively participating in
more than 70 afliates around the country. Through suchvolunteer support, more than $6 million (gross) was raised in
FY 2009-'10 through fundraising events that also generated
signicant awareness.
To ensure our volunteers receive the best resources
and support possible, the Volunteer Advisory Council (VAC),
comprising 15 volunteers from afliates around the country,
provides invaluable leadership and insight throughout
the year. We rely on the perspective and guidance of
VAC members when making many decisions affecting our
volunteers, said Mary Jo Kennedy, Director of Community
Outreach.
This year, they were particularly instrumental inshaping our Community Outreach Leadership Training, re-
crafting the volunteer newsletter and Toolbox, revising our
comprehensive event e-blast policy, and developing branding
for our PurpleStride and TEAMHOPE events, she added.
I was thrilled to be invited onto the Volunteer Advisory
Council, Tammy Andries, a Madison volunteer and a
pancreatic cancer survivor, said. I have a background in
media and marketing and hoped I could make it easier for
other afliates to raise the awareness of this disease. What I
like is that we all have a voice in the Pancreatic Cancer ActionNetwork. We can talk with our volunteers and share their
suggestions or concerns and we know we are being heard."
In addition to Tammy, other VAC members include:
Ayme Zemke, Twin Cities Media Representative
Christina Tabarrini, Philadelphia Co-Afliate Coordinator
Debbie Herrero and Nicole Trella, New Jersey Afliate
Co-coordinators
Gael Sandoval, Detroit Afliate Coordinator
Greg Petrosewicz, Austin Afliate Coordinator
Gretchen Guerra, past Denver Afliate CoordinatorJay Stern, Oklahoma Afliate Coordinator
John Cravero, Chicago Afliate Coordinator
Ken Cunzeman, Baltimore Afliate Coordinator
Michelle Monhart, Bay Area Afliate Coordinator
Sandra Martin, Florida, Tampa Bay Afliate Coordinator
Stephanie Pisarski, St. Louis Event Coordinator
Susan Okula, National Capital Area Afliate Coordinator
-
7/31/2019 Outreach Oct 2010
13/16
October 2010 OUTREACH 11
CALIFORNIA8th Annual Walk Through the Vineyards, St. Helena,
6/12/2010
3rd Annual Day With the Sacramento Rivercats, 6/20/2010
Awareness Day With the Angels, Anaheim, 7/17/2010
Timothy J. Marsh Fishing For A Cure, San Diego, 7/17/2010
3rd Annual Fundraiser for a Cure in Memory of Bridget
Fisher, Anaheim, 8/1/2010
Awareness Night With the Giants, San Francisco, 7/30/2010
Strikeout Pancreatic Cancer With the OC Flyers, Fullerton,
8/21/2010
Awareness Night With the Dodgers, Los Angeles, 9/3/2010
Awareness Night With the Los Angeles Galaxy, 9/11/2010
PurpleNight Out at Coyote Cantina, Redondo Beach,
9/27/2010
COLORADO
PurpleStride Pikes Peak 2010, Colorado Springs,
7/31/2010
PurpleStride Western Slope 2010, Montrose, 8/21/2010
PurpleStride Golden Gallop 2010, Golden, 9/11/2010
DISTRICT OF COLUMBIA
PurpleStride Washington, D.C. 2010, 6/19/2010
FLORIDA
Awareness Night With the Manatees, Viera, 7/17/2010Art for the Cure, Altamonte Springs, 8/28/2010
PurpleStride Jacksonville 2010, 9/18/2010
IDAHO
Awareness Night with the Boise Hawks, 8/14/2010
PurpleRide Spoke-d'Alene 2010, Spokane to Coeur
d'Alene, 8/28/2010
IOWA
PurpleStride Iowa 2010, West Des Moines, 9/25/2010
LOUISIANA
Corks N Canvas, Baton Rouge, 7/25/2010
Awareness Night With the Zephyrs, Metairie, 7/29/2010
MARYLAND
PurpleSwim Baltimore 2010 In Memory of Bud Beatty,
8/8/2010
PurpleStride Maryland 2010, Cockeysville, 10/10/2010
MASSACHUSETTS
Dough-Raisers Fundraiser at Uno Chicago Grill, Boston,
6/6/2010
Potluck Family Picnic, Pine Banks Park, 8/28/10
MICHIGANPurpleStride Detroit 2010, 9/12/2010
MINNESOTA
Awareness Night With the Twins, 7/17/2010
PurpleRide Twin Cities 2010, 9/19/2010
PurpleStride Rochester 2010, 9/26/2010
MISSOURI
Hospital Hill Run 2010, Kansas City, 6/5/2010
Purple Night Out 2: St. Louis, Rock Hill, 6/23/2010
Awareness Day With the Cardinals, St. Louis, 8/13/2010
NORTH CAROLINA
PurpleBowl Raleigh-Durham 2010, 8/14/2010
NEW JERSEY
Awareness Day With the Somerset Patriots, 7/18/2010
NEW YORK
Awareness Night With the New York Mets, 7/28/2010
PurpleStride Long Island 2010 in Memory of Jimi Lee,
9/26/2010
OHIO
PurpleStride Cleveland 2010, 6/12/2010
Garage Sale, Worthington, 7/17/2010
PurpleStride Central Ohio 2010, Clifton, 9/18/2010
PENNSYLVANIA
Awareness Night With the Pittsburgh Pirates, 6/18/2010
PurpleStride Pittsburgh 2010 "Pick Up The Pace",
8/15/2010
Awareness Night With NEPA Miners Football, 8/14/2010
TENNESSEE
PurpleStride Chattanooga 2010, 10/10/2010
TEXAS
Awareness Night With the Round Rock Express, 7/21/2010
PurpleStride Austin 2010, 9/25/2010
WASHINGTON
Awareness Day With the Seattle Mariners, 8/29/2010
WEST VIRGINIA
Purple Power Night 2010, Charleston, 7/9/2010
WISCONSIN
Night at Tazino's, Oak Creek, 6/9/2010
Awareness Night With the Mallards, Madison, 8/11/2010
PurpleStride Madison 2010, 9/19/2010
EVENTS SUMMARYJUNE SEPTEMBER 2010
-
7/31/2019 Outreach Oct 2010
14/16
12 October 2010 OUTREACH
A wonderful way to pay ongoing tribute to your loved one while raisingawareness and funding for the ght against pancreatic cancer.
www.rstgiving.com/keepthememoryalive
KEEP THE MEMORY ALIVE
CORPORATE CHAMPIONS CONTINUE THE FIGHTThe second annual Tempur-
Pedic Hugs Back campaign
launched this month with
the release of a new andvery cuddly cream-colored
teddy bear. The company
is again joining with their
retailers across the country to participate in the well-received
awareness and fundraising initiative.
Thanks to Tempur-Pedic retailers who participated in the rst
campaign last year, the 2009 Hugs Backcampaign generated
essential nancial support for our inaugural Pathway to
Leadership award, a ve-year research grant that was given
to Zeshaan Rasheed, MD, PhD, a leading pancreatic cancer
researcher at Johns Hopkins University, said Pamela Acosta
Marquardt, Founder and Director of Donor and Corporate
Relations. By helping to fund this grant, Tempur-Pedic and
these retailers made an immediate and indelible impression
on research into the disease.
One of our organization's research priorities is to attract
brilliant scientists and help them develop successful careers
in pancreatic cancer research, added Julie Fleshman,
President and CEO. We are very thankful to Tempur-Pedic
and their generous retailers for helping us to further this goal.
The Hugs Back campaign continues to generate tremendous
excitement and hope throughout the pancreatic cancer
community.
Tempur-Pedic is the Pancreatic Cancer Action Networks rst
national corporate sponsor to make a substantial, multi-year
commitment to the ght against the disease.
This year's Hugs Back campaign begins on October
15 and will run throughout the fall while supplies of the
teddy bears last. Volunteers and supporters nationwide are
encouraged to visit their local participating Tempur-Pedic
retailer and give them some hugs back to thank them fortheir support of and commitment to our cause.
For more information about the 2010 Tempur-Pedic Hugs
Backcampaign, visit www.tempurpedichugsback.com .
NHL HOCKEY FIGHTS CANCERNAMED AS CHARITABLE LEAGUE
PARTNER
The National Hockey League (NHL)
and the NHL Players' Association
have named the Pancreatic Cancer
Action Network as a charitable league partner for their
Hockey Fights Cancer Awareness Month during October for
the upcoming 2010-'11 season. In addition, the NHL and
NHL Players' Association will partially fund a pancreatic
cancer research grant through a generous donation to the
organization.
Were thrilled to be working with the NHL to bring much-
needed national attention to this dreadful disease and are very
grateful to both the NHL and NHL Players' Association for
their support and generosity, said Brian Doremus, Director
of Corporate Relations. As part of Hockey Fights Cancer
Awareness Month, the NHL league ofce has also asked NHL
member teams to help Pancreatic Cancer Action Network
volunteer afliates across the country raise awareness and
funds during October.
Hockey Fights Cancer is a component of the NHL's "Biggest
Assist Happens Off the Ice" campaign, the league's long-
standing tradition of addressing important social issues in
North America and worldwide.
Hockey Fights Cancer is a joint initiative by the NHL and
the NHL Players' Association to raise money and awareness
for hockey's most important ght. To date, more than
$11 million has been raised to support national and local
cancer research institutions, children's hospitals, player
charities and various cancer organizations.
To learn more, visit www.nhl.com and click on HockeyFights Cancer.
-
7/31/2019 Outreach Oct 2010
15/16
October 2010 OUTREACH 13
On January 22, 1997, my husband, Randy Stein, was diag-
nosed with stage-four, inoperable pancreatic cancer, with
metastases to the spleen and kidneys. At that time, the doc-
tors told us he only had three months to live.
Healthcare professionals, friends, and family tried to help,
but they really didnt have any experience in dealing with the
disease. The Internet only provided dire statistics and we did
not know of any survivors. Ultimately, we found great medical
care, and we dealt with each challenge as it presented itself.
In spite of that frightening news and the lack of information
available back then, Randy lived for more than eight years
following his diagnosis.
Those years were lled with travel and celebrations, and we
appreciated each day because we gained new insight into
the importance of living. During our journey, we met a woman
named Pamela Acosta Marquardt, who had just founded the
Pancreatic Cancer Action Network, and she asked us to get
involved. This opportunity enabled us to help create a sorely
needed resource for information on the disease and to help
support awareness for a cancer that had previously been
ignored.
We joined other patients, caregivers, and activists in this ef-
fort and found great satisfaction in giving back. We raisedmoney through the organizations annual An Evening with the
Stars gala, and traveled to Washington, D.C. to advocate for
more federal funding for research. Randy sat on the board of
directors as the organizations rst treasurer. After his death,
I became a board member to continue to provide hope anddirection to others.
During the most trying time of our life together, the
Pancreatic Cancer Action Network offered us a lifeline for
support, and we were able to connect with hundreds of
others who were in our same situation. Over the years, the
organization grew, and became the national leader in the
ght against the disease.
After Randys death, I wanted to do something meaningful
to keep his memory alive. I really wanted to make a large
donation to the Pancreatic Cancer Action Network becauseit had been such a large part of our lives, but I knew Randy
would want me to take care of myself rst nancially. After
careful consideration, I came up with a plan to meet both of
these goals.
I began donating money to the Pancreatic Cancer Action
Network as my nances allowed and volunteering whenever I
could. Eventually, I decided to donate part of my estate to the
organization. When I was making these preparations, I found
there were many types of other planned giving vehicles, too.
I even found some that could provide income for me for the
rest of my life and support the organization at the same time.Having the Pancreatic Cancer Action Network in my will en-
ables me to always feel connected to the cause while still
being able to go on with my life like Randy would have wanted.
I know that this organization will always be a part of my life,
so I am glad to support it in any way I can. Hopefully, my
contributions will help the Pancreatic Cancer Action Network
to continue fullling its mission until a cure is found.
Find out how easy it is to create a legacy that will touch
many lives for years to come. To learn more, call Pamela
Acosta Marquardt at 877-272-6226 or e-mail her at
REMEMBERING RANDY: A LEGACY OF LOVE
Randy and Judy Stein
CREATE A LEGACY GIFTA legacy gift ensures that your estate will benet countless lives affected by pancreatic canc
A planned gift to the Pancreatic Cancer Action Network is a wonderful way to help us fulll o
important mission. To learn more about creating a bequest, or other planned giving options, plea
contact Pamela Acosta Marquardt at [email protected] or at 877-272-6226.
-
7/31/2019 Outreach Oct 2010
16/16
MAKE EVERY
AWARENESS COUNJoin us to know it, ght it, end it and
make awareness count all the time. S
our online store for your purple app
accessories, and more.
WWW.PANCAN.ORG/STORE
Non-Prot Org
US Postage
PAID
Torrance, CA
Permit No.473
2141 Rosecrans Ave., Ste 7000, El Segundo, CA 90245
CALENDAR OF EVENTSDATE EVENT NAME CITY, STATE CONTACT
10/17/2010 6th Annual "Time for Hope" Benet Oak Forest, IL Audrey Montalto at [email protected]
10/17/2010 PurpleStride St. Louis 2010 St. Louis, MO Stephanie Pisarski at [email protected]
11/4/2010 4th Annual Night of Hope - Tampa Bay 2010 Tampa, FL Carol Ferguson at [email protected]
11/6/2010 PurpleStride South Florida Davie/Ft. Lauderdale, FL Kimberly Spelman at [email protected]
11/6/2010 PurpleStride Savannah 2010 Tybee Island, GA Shelly Foster at [email protected]
11/6/2010 PurpleStride Philadelphia 2010 Philadelphia, PA Donna Deoria at [email protected]
11/6/2010 PurpleStride San Antonio 2010 San Antonio, TX Jenny Finkbiner at [email protected]
11/6/2010 Jazzed for Hope 2010 Madison, WI Julie Jacobs at [email protected]
11/7/2010 PurpleStride Orlando 2010 Orlando, FL Diane Germ at [email protected]
11/7/2010 PurpleStride Raleigh-Durham 2010 Raleigh, NC Marisa Grant at [email protected]
11/7/2010 PurpleStride Danbury 2010 Danbury, CT Kristen Angell at [email protected]
11/7/2010 PurpleStride New Jersey 2010 Parsippany, NJ Nicole Trella at [email protected]
11/7/2010 PurpleStride Portland 2010 Portland, OR Ariane Chapple at [email protected]
11/7/2010 PurpleStride Puget Sound 2010 Bellevue, WA Chelsea Orvella at [email protected]
11/13/2010 PurpleStride Atlanta 2010 Atlanta, GA Nancy Freedman at [email protected]
11/13/2010 PurpleStride Orange County 2010 Irvine, CA Roberta Luna at [email protected]
11/13/2010 PurpleStride San Diego 2010 Bonita, CA Lily Villaverde at [email protected]
11/14/2010 PurpleStride DFW 2010 Dallas, TX Mary Jo Jennings at [email protected]
12/5/2010 PurpleStride Lake Area 2010 Lake Charles, LA Kristi Remy at [email protected]
TO CONTACT USIf your address is incorrect, or you are receiving duplicate
of this publication, you may submit changes in one of thre
e-mail [email protected]; update the label and mail it
reach/ PanCAN, 2141 Rosecrans Ave., Suite 7000, El Segu
90245; or call 877-272-6226. By giving the code number
pears above your name, your request can be processed
Thank you for helping us to manage our expenses.